NantCare, a member of the NantWorks will be providing community oncology practices with solutions and resources that will help these practices comply with the administrative and clinical requirements put forth by the CMS’ new Oncology Care Model (OCM). Typically only available at large cancer institutions, NantCare will provide access to clinical trials through facilitation of participation in Cancer MoonShot 2020’s QUILT Trials, eliminating the need for patients to travel to major cancer centers for care and treatment.
The Center for Medicare & Medicaid Innovation (CMS Innovation Center) has established the Oncology Care Model, which aims to provide higher quality, more highly coordinated oncology care at the same or lower cost to Medicare. The goal of OCM is to utilize appropriately aligned financial incentives to enable improved care coordination, appropriateness of care and access to care for beneficiaries undergoing chemotherapy.
The NantCare OCM solutions bring sophisticated resources and technologies to assist community oncology practices to more efficiently and effectively comply with the administrative and clinical requirements of the CMS’s OCM – resources that are often otherwise available only to large cancer institutions.
Today, 85 percent of oncology care is provided in the community oncology setting and only about three percent of all oncology patients enter into a clinical trial. NantCare’s work to support community oncology practices aims to change that by facilitating practices’ participation in QUILT Trials and by making it easier for patients to participate in clinical trials by not having to travel long distances to major cancer centers for care.
“Our work with community oncology practices opens up the possibility that patients can get access to sophisticated QUILT Trials in the community setting,” stated Carla Balch, President of NantCare. “QUILT can be a vibrant part of the Oncology Care Model; and the innovative approach of QUILT is uniquely well-suited for community oncology. Dr. Soon-Shiong has always been very supportive of the community setting and we believe it’s our priority to do all we can to empower community oncologists with the most advanced science and technology resources available.”
NECS, the largest community practice in Maine with over 3,000 new patients with approximately 50,000 cancer patient visits a year, will receive support which will be made available to all OCM practices including:
– Real-World Big Data Infrastructure (Terabyte Speed Fiber)
– Real-Time Next Generation Bioinformatics (Super Computing)
– HIPAA-Secured Cloud (Distributed Storage)
– Immuno-Oncology Translational & Basic Science (Cutting Edge Science)
– Access to Novel Immuno-Oncology Molecules Transcending the Innate & Adaptive Immune System (60 Novel Agents)
– Cutting-Edge Clinical Trials Combining Novel Novel Agents Across all Tumor Types (Regulatory & Clinical Trial Support)
– Next-Generation Certified Clinical Immuno-Oncologists with Knowledge of 21st Century Immuno-Oncology (Next Generation Clinical Scientists)
Some of the resources provided by NantCare include decision-support with near real-time bioinformatics and evidence-based protocols that enable the clinician to potentially make more optimal treatment decisions while understanding the economic impact of the treatment, especially as the treatment choices relate to nationally recognized guidelines and clinical trials (including Cancer MoonShot 2020 QUILT Trials).
Trial Match provides clinical trial matches for patients (including molecular and proteomic data) and an overview of the patient population at the practice, which allows NantCare to open trials that match the overall patient population of each practice. Ordering of GPS Cancer is enabled through physician’s electronic medical records or directly through a convenient web portal. Additionally, the National Tumor Board is available to support any physician ordering GPS Cancer.